SCHEMBL7186732

SCHEMBL7186732

COc1ccc(PC(=O)c2c(OC)cc(OC)cc2OC)cc1.[LiH]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
USP2 O75604 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ABCG2 Q9UNQ0 2/20 0.46
NPC1 O15118 2/20 0.44
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
DPP4 P27487 1/20 0.43
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180801 0.91 CYP3A4 (0.44) KMT2ACYP3A4CYP2D6CYP2C19USP2
SCHEMBL7185189 0.89 KMT2A (0.47) KMT2ACYP3A4CYP2D6CYP2C19USP2
SCHEMBL7183427 0.89 MAPT (0.45) KMT2ACYP3A4CYP2D6CYP2C19USP2
SCHEMBL7182033 0.89 KMT2A (0.43) KMT2ACYP3A4CYP2D6CYP2C19USP2
SCHEMBL7180710 0.89 KMT2A (0.43) KMT2ACYP3A4CYP2D6CYP2C19USP2
SCHEMBL7190348 0.89 LTA4H (0.45) KMT2ACYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL7175851 0.87 KMT2A (0.45) KMT2ACYP3A4CYP2D6CYP2C19USP2
SCHEMBL7175420 0.87 CA12 (0.49) KMT2AUSP2SMN1; SMN2NPC1ALDH1A1
SCHEMBL7185185 0.87 KMT2A (0.43) KMT2ACYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL7189363 0.86 SLC5A1 (0.43) KMT2ACYP3A4CYP2D6CYP2C19GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885CYP3A4 1652/4885CYP2D6 1673/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885CYP3A4 1881/4885CYP2D6 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.